The First Trust NYSE Arca Biotechnology Index Fund (FBT) and the iShares Biotechnology ETF (IBB) differ significantly in strategy and performance. FBT uses an equal-weight approach across about 30 biotech stocks, emphasizing innovation and smaller companies, while IBB concentrates nearly 30% of assets in four large drugmakers, favoring stability and cash flow. This difference has led FBT to outperform IBB by over 34 percentage points in returns over five years, though with higher volatility. Investors seeking growth and exposure to biotech innovation may prefer FBT, while those wanting steadier returns with less risk might choose IBB.
The SPDR S&P Biotech ETF (XBI) and Invesco Biotechnology & Genome ETF (PBE) differ significantly in portfolio structure and performance. XBI uses a modified equal-weight approach across 100+ biotech stocks, favoring small- and mid-cap clinical-stage ...
Small- and mid-cap stocks are leading gains in 2026, with earnings estimates rising after 10 quarters of decline. These stocks currently trade 20% to 35% below large caps, offering potential for growth from lower valuations. The T. Rowe Price Small-M...
